OTTAWA – Health Canada initiated a safety review for the prescription diabetes drugs dapagliflozin (Forxiga) and canagliflozin (Invokana) and the risk of ketoacidosis, a serious condition that leads to high levels of blood acids called ketones. Dapagliflozin and canagliflozin are known as SGLT2 (sodium-glucose cotransporter-2) inhibitors and are approved in Canada for use in patients […]Read More